View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2012	Oct. 29, 2012
Document Documentand Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2012
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q3
Trading Symbol	SCMP
Entity Registrant Name	Sucampo Pharmaceuticals, Inc.
Entity Central Index Key	0001365216
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		41,905,364

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2012	Dec. 31, 2011
Current assets:
Cash and cash equivalents	$ 57,246	$ 50,662
Investments, current	6,229	24,452
Product royalties receivable	13,346	10,795
Unbilled accounts receivable	571	2,036
Accounts receivable, net	1,235	4,616
Prepaid and income taxes receivable	3,316	2,845
Deferred tax assets, current	33	163
Deferred charge, current	673	3,057
Restricted cash, current	15,113	15,113
Prepaid expenses and other current assets	2,611	1,177
Total current assets	100,373	114,916
Investments, non-current		998
Property and equipment, net	1,563	1,669
Intangibles assets, net	7,660	8,364
Deferred tax assets, non-current	1,728	2,089
Deferred charge, non-current	5,381	26,751
Restricted cash, non-current	3,548	2,129
Other assets	878	653
Total assets	121,131	157,569
Current liabilities:
Accounts payable	3,455	6,978
Accrued expenses	8,800	13,648
Deferred revenue, current	3,841	3,888
Deferred tax liability, current	51	2,167
Notes payable, current	20,300	20,400
Total current liabilities	36,447	47,081
Notes payable, non-current	40,883	39,227
Deferred revenue, non-current	7,101	7,045
Deferred tax liability, non-current	5,125	23,019
Other liabilities	2,211	2,603
Total liabilities	91,767	118,975
Commitments and contingencies (Notes 7 and 10)
Stockholders' equity:
Additional paid-in capital	61,723	59,957
Accumulated other comprehensive income	16,110	17,854
Treasury stock, at cost; 310,122 and 186,987 shares at September 30, 2012 and December 31, 2011, respectively	(1,256)	(700)
Accumulated deficit	(47,632)	(38,936)
Total stockholders' equity	29,364	38,594
Total liabilities and stockholders' equity	121,131	157,569
Class A Common Stock [Member]
Stockholders' equity:
Common stock	$ 419	157
Class B Common Stock [Member]
Stockholders' equity:
Common stock		$ 262

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2012	Dec. 31, 2011
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, shares issued	0	0
Treasury stock, shares	310,122	310,122
Class A Common Stock [Member]
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	270,000,000	270,000,000
Common stock, shares issued	41,901,785	15,690,780
Common stock, shares outstanding	41,901,785	15,690,780
Class B Common Stock [Member]
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	0	75,000,000
Common stock, shares outstanding	0	26,191,050

Condensed Consolidated Statements Of Comprehensive Income (Loss) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Revenues:
Research and development revenue	$ 737,000	$ 2,885,000	$ 6,418,000	$ 6,591,000
Product royalty revenue	13,890,000	10,563,000	36,521,000	30,724,000
Co-promotion revenue	730,000	769,000	3,253,000	2,768,000
Contract and collaboration revenue	139,000	155,000	433,000	463,000
Total revenues	15,496,000	14,372,000	46,625,000	40,546,000
Operating expenses:
Research and development	5,615,000	8,725,000	14,202,000	25,838,000
General and administrative	7,256,000	7,926,000	22,598,000	29,317,000
Selling and marketing	4,278,000	2,243,000	14,474,000	6,689,000
Total operating expenses	17,149,000	18,894,000	51,274,000	61,844,000
Income (loss) from operations	(1,653,000)	(4,522,000)	(4,649,000)	(21,298,000)
Non-operating income (expense):
Interest income	68,000	35,000	118,000	160,000
Interest expense	(596,000)	(619,000)	(1,780,000)	(1,844,000)
Other income (expense), net	8,000	1,224,000	727,000	(2,033,000)
Total non-operating income (expense), net	(520,000)	640,000	(935,000)	(3,717,000)
Loss before income taxes	(2,173,000)	(3,882,000)	(5,584,000)	(25,015,000)
Income tax benefit (provision)	(3,776,000)	(196,000)	(3,112,000)	5,009,000
Net loss	$ (5,949,000)	$ (4,078,000)	$ (8,696,000)	$ (20,006,000)
Net loss per share:
Basic net loss per share	$ (0.14)	$ (0.10)	$ (0.21)	$ (0.48)
Diluted net loss per share	$ (0.14)	$ (0.10)	$ (0.21)	$ (0.48)
Weighted average common shares outstanding - basic	41,678	41,877	41,697	41,864
Weighted average common shares outstanding - diluted	41,678	41,877	41,697	41,864
Comprehensive loss:
Net loss	$ (5,949,000)	$ (4,078,000)	$ (8,696,000)	$ (20,006,000)
Other comprehensive income (loss):
Unrealized gain on investments, net of tax effect	28,000	100,000	23,000	108,000
Foreign currency translation	(175,000)	(2,121,000)	(1,767,000)	1,161,000
Comprehensive loss	$ (6,096,000)	$ (6,099,000)	$ (10,440,000)	$ (18,737,000)

Condensed Consolidated Statement Of Changes In Stockholders' Equity - 9 months ended Sep. 30, 2012 - USD ($) $ in Thousands	Class A Common Stock [Member]	Class B Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]	Total
Beginning Balance (in shares) at Dec. 31, 2011	15,690,780	26,191,050			186,987
Beginning Balance at Dec. 31, 2011	$ 157	$ 262	$ 59,957	$ 17,854	$ (700)	$ (38,936)	$ 38,594
Conversion of shares (in shares)	26,191,050	(26,191,050)
Conversion of shares	$ 262	$ (262)
Employee stock option expense			1,683				1,683
Stock issued upon exercise of stock options (in shares)	17,484
Stock issued upon exercise of stock options			67				67
Stock issued under employee stock purchase plan (in shares)	2,471
Stock issued under employee stock purchase plan			16				16
Foreign currency translation				(1,767)			(1,767)
Unrealized gain on investments, net of tax effect				23			23
Treasury shares purchased, not retired (in shares)					123,135
Treasury shares purchased, not retired					$ (556)		(556)
Net loss						(8,696)	(8,696)
Ending Balance (in shares) at Sep. 30, 2012	41,901,785				310,122
Ending Balance at Sep. 30, 2012	$ 419		$ 61,723	$ 16,110	$ (1,256)	$ (47,632)	$ 29,364

Condensed Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Cash flows from operating activities:
Net loss	$ (8,696)	$ (20,006)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,105	1,026
Deferred tax provision	(19,511)	12
Deferred charge	23,754	(7,774)
Stock-based compensation	1,683	926
Amortization of premiums on investments	49	600
Notes payable paid-in-kind interest	1,656	1,719
Changes in operating assets and liabilities:
Accounts receivable	3,381	(408)
Unbilled accounts receivable	1,464	(676)
Product royalties receivable	(2,551)	(47)
Inventory	87
Prepaid and income taxes receivable and payable, net	(467)	2,340
Accounts payable	(3,513)	2,144
Accrued expenses	(1,853)	5,403
Deferred revenue	(45)	(2,994)
Other assets and liabilities, net	(1,711)	656
Net cash used in operating activities	(5,168)	(17,079)
Cash flows from investing activities:
Purchases of investments	(5,929)	(20,598)
Proceeds from sales of investments	750	7,380
Maturities of investments	24,345	40,205
Purchases of property and equipment	(306)	(284)
Proceeds from disposals of property and equipment		79
Purchases of intangible assets	(3,000)	(3,000)
Purchase of other investing activities	(432)
Restricted cash	(1,364)	(2,286)
Issuance of notes receivable		(100)
Net cash provided by investing activities	14,064	21,396
Cash flows from financing activities:
Proceeds from exercise of stock options	67	98
Proceeds from employee stock purchase plan	15	8
Purchase of treasury stock	(556)	(149)
Net cash used in financing activities	(474)	(43)
Effect of exchange rates on cash and cash equivalents	(1,838)	1,750
Net increase in cash and cash equivalents	6,584	6,024
Cash and cash equivalents at beginning of period	50,662	49,243
Cash and cash equivalents at end of period	57,246	55,267
Supplemental disclosure of non-cash investing and financing activities:
Purchase of intangible assets included in accrued expenses		$ 3,000
Purchase of other investing activities included in accounts payable	$ 2

Business Organization And Basis Of Presentation	9 Months Ended
Business Organization And Basis Of Presentation	Sep. 30, 2012
Business Organization And Basis Of Presentation [Abstract]
Business Organization And Basis Of Presentation	1.Business Organization and Basis of Presentation Description of the Business Sucampo Pharmaceuticals, Inc., or the Company, is a global pharmaceutical company focused on innovative research, discovery, development and commercialization of proprietary drugs based on prostones and other novel drug technologies. The therapeutic potential of prostones was first discovered by the Company’s cofounder, Dr. Ryuji Ueno, and under his leadership the company has pioneered the field of prostones. Prostones are naturally occurring fatty acid metabolites. Originally thought to be biologically inert, prostones have emerged as a promising compound class with unique physiological activities which can be targeted for the treatment of unmet or underserved medical needs. Prostones act locally to restore normal function in cells and tissues, and because they are quickly metabolized to an inactive form, their pharmacologic activity can be targeted to specific organs and tissues. They possess a unique mechanism of action as highly potent and selective ion channel activators. Ion channels are integral parts of cell membranes that regulate the flow of specific ions into and out of cells. This regulation is key to the functioning of cells, such as metabolic processes and cell survival. As such, prostones are physiological mediators of the restoration of cellular homeostasis and tissue regeneration. There is also evidence that prostones have anti-inflammatory properties and can prevent cell death. The Company’s prostone-based compounds target the ClC-2 and BK ion channels. Because these ion channels play an important role in physiology, targeted dosing of prostones may have broad applicability in many disease states in different organ systems. The Company has developed synthetic analogs of the naturally occurring prostones, which have been optimized to be more potent, selective, and stable, thus enabling their use as drugs. Prostones are very selective for their molecular targets, and the approved prostone-based compounds are well-tolerated and generally safe. The Company is focused on developing prostones to treat gastrointestinal, ophthalmologic, central nervous system, and vascular diseases, as well as considering other potential therapeutic applications. The Company currently generates revenue mainly from product royalties, development milestone payments, and clinical development activities. The Company expects to also generate revenue in the future from the sale of product. The Company expects to continue to incur significant expenses for the next several years as the Company continues its research and development activities and seeks regulatory approvals for additional indications for AMITIZA^®(lubiprostone), RESCULA^® (unoprostone isopropyl) and other compounds, and commercializes approved products on a global basis. To date, two prostone products have received marketing approval, AMITIZA^® and RESCULA®. A third prostone, cobiprostone, or SPI-8811, is currently in clinical development for the target indication of the prevention of oral mucositis. The Company’s orphan drug application for cobiprostone for oral mucositis is under review with the U.S. Food and Drug Administration, or FDA. Two additional prostones, SPI-017 and SPI-3608, have also been developed for human testing for the indication of the management of pain caused by spinal stenosis. AMITIZA is being marketed in the U.S. for two gastrointestinal indications under the October 2004 collaboration and license agreement with Takeda Pharmaceutical Company Limited, or Takeda Agreement. These indications are chronic idiopathic constipation, or CIC, in adults and irritable bowel syndrome with constipation, or IBS-C, in adult women. Takeda also holds marketing rights to AMITIZA in Canada, but has not yet commercialized it there. The Company is primarily responsible for clinical development activities under the Takeda Agreement while Takeda is responsible for commercialization of AMITIZA in the U.S. and Canada. The Company and Takeda initiated commercial sales of AMITIZA in the U.S. for the treatment of CIC, in April 2006 and for the treatment of IBS-C in May 2008. In July 2012, the Company filed a supplemental new drug application, or sNDA, with the FDA seeking priority review of a new, third indication for the use of AMITIZA in the treatment of opioid-induced constipation, or OIC. In September 2012, the FDA accepted the sNDA and agreed to a priority review, which is expected to be completed in late January 2013. In Japan, lubiprostone is being developed and marketed under a license, commercialization and supply agreement, or the Abbott Agreement, with Abbott Japan Co. Ltd., or Abbott, for the treatment of chronic idiopathic constipation, or CIC, in Japan. The Company received approval of its new drug application, or NDA, for AMITIZA for the treatment of chronic constipation, or CC, excluding constipation caused by organic diseases, from the Ministry of Health, Labour and Welfare, or MHLW, in June 2012. The Company is currently engaged in pricing negotiations with Japanese authorities, and expects those negotiations to conclude in the fourth quarter of 2012. In that event, the Company anticipates a launch by Abbott in the fourth quarter of 2012. Because the approval includes CIC and other indications such as OIC, the Company is evaluating options for the commercialization of the additional indications. Abbott has the right of first refusal for a limited time period of exclusive negotiations for indications other than OIC and IBS-C. If Abbott declines to negotiate for those other indications or there is no agreement reached regarding the other indications, the Company has the right to negotiate with third parties for the other indications, or market those indications itself as is the case with OIC and IBS-C. Abbott has 45 days to meet the terms and conditions of any third party bona fide offer. In Europe, the Company has marketed AMITIZA, on a limited basis, in Switzerland since February 2012 while the Company continued discussions with the Swiss Federal Office of Public Health for pricing approval. The Company expects to conclude the pricing discussions in the fourth quarter of this year and therefore enable greater patient access for AMITIZA in this market. In the U.K., the Company received approval in September 2012 from the Medicines and Healthcare products Regulatory Agency, or MHRA, for the use of AMITIZA to treat CIC. The Company intends to actively market AMITIZA in the U.K. in the first quarter of 2013. In the meantime AMITIZA is being made available through a Named Patient Program throughout the E.U., Iceland and Norway. The Company plans to commence the approval process in other E.U countries for CIC via the Mutual Recognition Procedure, or MRP. The Company plans to file for the OIC indication in Switzerland and the U.K. during the fourth quarter of 2012. The Company holds license agreements for RESCULA in the United States and Canada and the rest of the world, with the exception of Japan, Korea, Taiwan and the People’s Republic of China. In the U.S., RESCULA is approved for the lowering of intra-ocular pressure, or IOP, in open-angle glaucoma and ocular hypertension in patients who are intolerant of or insufficiently responsive to other IOP-lowering medications. The Company’s discussions with the FDA under the sNDA have resulted in a FDA complete response letter that made improvements to the label. These improvements include removal of second line therapy language to enable first line use, removal of the prostaglandin description, and additions to the mechanism of action section. During the quarter ended September 30, 2012, the Company awaits a complete response letter from the FDA, currently anticipated to be received by the end of 2012. The FDA’s action will reflect discussions with the FDA concerning updates to the product’s label and clearance of the product’s manufacturer, R-Tech Ueno, Ltd, or R-Tech, facility. The Company plans to launch RESCULA in the U.S. shortly after the approval of the sNDA. The Company is also evaluating the opportunities to obtain an appropriate label in the E.U. and other European countries, and the timing of seeking reauthorization in those countries to commercialize unoprostone isopropyl. In other areas of development, the Company entered into agreements in 2011 with CuroNZ of New Zealand, which may augment the Company’s ophthalmic development opportunities, and Numab AG, or Numab of Switzerland, to obtain access to their proprietary technology for the discovery of high-affinity antibodies against certain selected targets. Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP, and the rules and regulations of the Securities and Exchange Commission, or SEC, for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company’s Consolidated Financial Statements as of and for the year ended December 31, 2011 included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on March 15, 2012. The financial information as of September 30, 2012 and for the three and nine months ended September 30, 2012 and 2011 is unaudited. In the opinion of the Company’s management, all adjustments, consisting only of normal recurring adjustments or accruals, considered necessary for a fair statement of the results of these interim periods have been included. The results of the Company’s operations for any interim period are not necessarily indicative of the results that may be expected for any other interim period or for a full fiscal year. The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All significant inter-company balances and transactions have been eliminated. The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=7880789&loc=SL6228881-111685

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 272
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 15
-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 915
-SubTopic 235
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 94-6
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 2-6
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 46R
-Paragraph 4, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS140-4/FIN46(R)-8
-Paragraph 8, C1, C7
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Summary Of Significant Accounting Policies	9 Months Ended
Summary Of Significant Accounting Policies	Sep. 30, 2012
Summary Of Significant Accounting Policies [Abstract]
Summary Of Significant Accounting Policies	2.Summary of Significant Accounting Policies Cash and Cash Equivalents For the purpose of the Condensed Consolidated Balance Sheets and Statements of Cash Flows, cash equivalents include all highly liquid investments with a maturity of 90 days or less at the time of purchase. Restricted Cash Restricted cash consists of approximately $18.7 million and 17.2 million at September 30, 2012 and December 31, 2011, respectively. Restricted cash represents cash required to be deposited with certain financial institutions in connection with the Sucampo Pharma, Ltd., or SPL, loan agreement with The Bank of Tokyo-Mitsubishi UFJ, Ltd., Numab’s loan agreement with Zurcher Kantonalbank and operating leases. Current and Non-current Investments Current and non-current investments consist primarily of U.S. government agencies securities, corporate bonds, mutual funds and variable rate demand notes. The Company classifies its investments into current and non-current based on their maturities and management’s reasonable expectation to realize these investments in cash. The Company classifies all of its investments as available for sale securities and reports unrealized gains or losses, net of related tax effects, in other comprehensive income. Fair Value of Financial Instruments The carrying amounts of the Company’s financial instruments, which include cash and cash equivalents, restricted cash, current and non-current investments, receivables, accounts payable and accrued expenses, approximate their fair values based on their short maturities, independent valuations or internal assessments. The carrying amount of the short and long-term debt at September 30, 2012 and December 31, 2011 approximated its fair value due to the fact that the interest rates are determined based by reference to interbank rates. The Company’s debt is subject to the fair value disclosure requirements as discussed in Note 4 below, is considered a Level 2 security. Accounts Receivable and Unbilled Accounts Receivable Accounts receivable represent mainly amounts due under the Takeda and the Abbott Agreements. Unbilled accounts receivable represent the research and development expenses that are reimbursable by Takeda but have not been billed to Takeda as of the balance sheet date. The Company recorded an allowance for doubtful accounts at September 30, 2012 of approximately $192,000 related to certain disputed Takeda invoices. No allowance was recorded in 2011. Product Royalties Receivable Product royalties receivable represent amounts due from Takeda for the Company’s royalties on sales of AMITIZA, which are based on reports obtained directly from Takeda. Revenue Recognition The Company’s revenues are derived primarily from collaboration and license agreements and include upfront payments, development milestone payments, reimbursements of development and co-promotion costs and product royalties. The Company evaluated the multiple deliverables within the collaboration and license agreements in accordance with the guidance of multiple deliverables to determine whether the delivered elements that are the obligation of the Company have value to other parties to the agreement on a stand-alone basis and whether objective reliable evidence of fair value of the undelivered items exists. Deliverables that meet these criteria are considered a separate unit of accounting. Deliverables that do not meet these criteria are combined and accounted for as a single unit of accounting. The appropriate recognition of revenue is then applied to each separate unit of accounting. Royalty revenues are based on net sales of licensed products and are recorded on the accrual basis when earned in accordance with contractual terms when third-party results are reliably measurable, collectability is reasonably assured and all other revenue recognition criteria are met. Collaboration revenues relate to reimbursements of co-promotion costs based upon a rate per detail and reimbursements of the costs of miscellaneous marketing activities. The Company considers its participation in the joint committees under the collaboration and license agreements as separate deliverables under the contracts and recognizes the fair value of such participation as collaboration revenue over the period of the participation per the terms of the contracts. The Company has determined that it is acting as a principal under both the Takeda Agreement and Abbott Agreement and, as such, records revenue on a gross basis in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss). Contract Revenue Contract revenue relates to development and consulting activities and is accounted for under the time-based model. Certain Risks, Concentrations and Uncertainties Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents, restricted cash, investments and receivables. The Company places its cash, cash equivalents and restricted cash with highly rated financial institutions and invests its excess cash in highly rated investments. As of September 30, 2012 and December 31, 2011, approximately $4.6 million, or 5.6%, and $15.6 million, or 16.7%, respectively, of the Company’s cash, cash equivalents, restricted cash and investments were issued or insured by the federal government or government agencies. The Company has not experienced any losses on these accounts related to amounts in excess of insured limits. The Company’s products and product candidates under development require approval from the FDA or other international regulatory agencies prior to commercial sales. For those product candidates or indications that have not yet been approved by the FDA or international regulatory agencies, there can be no assurance the products will receive the necessary approval. If the Company is denied approval or approval is delayed, it may have a material adverse impact on the Company. The Company’s products, AMITIZA and RESCULA, compete in a rapidly changing, highly competitive market, which is characterized by advances in scientific discovery, changes in customer requirements, evolving regulatory requirements and developing industry standards. Any failure by the Company to anticipate or to respond adequately or timely to scientific developments in its industry, changes in customer requirements or changes in regulatory requirements or industry standards, or any significant delays in the development or introduction of products could have a material adverse effect on the Company’s business, operating results and future cash flows. The Company’s expected activities may necessitate significant uses of working capital. The Company’s working capital requirements will depend on many factors, including the successful sales of AMITIZA and RESCULA, research and development efforts to develop new products or indications, payments received under contractual agreements with other parties, the status of competitive products and market acceptance of the Company’s new products by physicians and patients. The Company plans to continue financing operations with its existing cash and investments as well as with product royalty revenue and cash received from milestones and other revenue related to its joint collaboration, license and supply agreements. Revenues from one unrelated party, Takeda, accounted for 98.7% and 97.6%, of the Company’s total revenues for the three months ended September 30, 2012 and 2011, respectively, and 98.0% and 96.6% for the nine months ended September 30, 2012 and 2011, respectively. Accounts receivable, unbilled accounts receivable and product royalties receivable from Takeda accounted for 96.0% and 100.0% of the Company’s total accounts receivable, unbilled accounts receivable and product royalties receivable at September 30, 2012 and December 31, 2011, respectively. Revenues from another unrelated party, Abbott, accounted for 0.1% and 1.7% of the Company’s total revenues for the three months ended September 30, 2012 and 2011, respectively, and 1.1% and 2.7% for the nine months ended September 30, 2012 and 2011, respectively. The Company depends significantly upon the collaborations with Takeda and Abbott and its activities may be impacted if these relationships are disrupted. The Company has an exclusive supply arrangement with R-Tech to provide it with commercial and clinical supplies of its product and product candidates. R-Tech also provides certain preclinical and other research and development services. Any difficulties or delays in performing the services under these arrangements may cause the Company to lose revenues, delay research and development activities or otherwise disrupt the Company’s operations.

Earnings Per Share

9 Months Ended

Sep. 30, 2012

Earnings Per Share [Abstract]

Earnings Per Share

3.Earnings per Share

Basic net income (loss) per share is computed by dividing net income (loss) by the sum of the weighted average class A and B common shares outstanding. On August 30, 2012, the Company announced the conversion of all the class B common stock into class A common stock on a one-to-one basis. Diluted net income per share is computed by dividing net income by the weighted average common shares and potential dilutive common shares outstanding. Diluted net loss per share, when applicable, is computed by dividing net loss by the weighted average common shares outstanding without the impact of potential dilutive common shares outstanding because they would have an anti-dilutive impact on diluted net loss per share.

The computation of net income (loss) per share for the three and nine months ended September 30, 2012 and 2011 is shown below:



		Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands of U.S. dollars, except per share data)		2012		2011		2012		2011
Basic net loss per share:
Net loss	$	(5,949)	$	(4,078)	$	(8,696)	$	(20,006)

Weighted average class A and B common shares
outstanding		41,678		41,877		41,697		41,864

Basic net loss per share		(0.14)		(0.10)		(0.21)		(0.48)

Diluted net loss per share:
Net loss	$	(5,949)	$	(4,078)	$	(8,696)	$	(20,006)

Weighted average class A and B common shares
outstanding for diluted net income per share		41,678		41,877		41,697		41,864

Diluted net loss per share		(0.14)		(0.10)		(0.21)		(0.48)

For the periods listed above, there were no potentially diluted securities to be used in the calculations of diluted historical net loss per share as of September 30, 2012 and 2011.

For the periods listed above, the following securities were excluded from the computation of diluted net loss per share as their effect would be anti-dilutive as of September 30, 2012 and 2011 are shown below:


	September 30,
(In thousands of U.S. dollars)	2012	2011
Employee stock options	3,578	3,427
Non-employee stock options	450	450

Current And Non-Current Investments

9 Months Ended

Sep. 30, 2012

Current And Non-Current Investments [Abstract]

Current And Non-Current Investments

4.Current and Non-Current Investments

At September 30, 2012 and December 31, 2011, current and non-current available-for-sale investments consisted of the following securities:


		September 30, 2012
				Unrealized		Unrealized
(In thousands of U.S. dollars)		Cost		Gains		Losses		Fair Value
Current:
U.S. commercial paper	$	1,999	$	-	$	-	$	1,999
Municipal securities		4,230		-		-		4,230
Total	$	6,229	$	-	$	-	$	6,229

		December 31, 2011
				Unrealized		Unrealized
(In thousands of U.S. dollars)		Cost		Gains		Losses		Fair Value
Current:
U.S. commercial paper	$	1,997	$	3	$	-	$	2,000
U.S. government securities		3,250		-		-		3,250
Corporate bonds		7,002		8		(3)		7,007
Variable rate demand notes		12,195		-		-		12,195
Total	$	24,444	$	11	$	(3)	$	24,452

Non-current:
U.S. government securities	$	1,000	$	-	$	(2)	$	998
Total	$	1,000	$	-	$	(2)	$	998

The Company performs fair value measurements in accordance with the relevant guidance for fair value measurements and disclosures, which defines fair value as the exchange price that would be received for selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy is established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company classifies its investments into the following categories based on the three levels of inputs used to measure fair value:

Level 1: quoted prices in active markets for identical assets or liabilities;

Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or

Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The Company’s assets measured at fair value on a recurring basis, which are subject to the fair value disclosure requirements, as of September 30, 2012 and December 31, 2011 are as follows:


		Fair Value Measurements at Reporting Date Using
September 30, 2012		Quoted Prices in Active Markets for identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
(In thousands of U.S. dollars)		(Level 1)		(Level 2)		(Level 3)		Total
U.S. government securities	$	-	$	-	$	-	$	-
U.S. commercial paper		-		3,499		-		3,499
Corporate bonds		-		1,203		-		1,203
Money market funds		22,440		-		-		22,440
Variable rate demand notes		-		4,230		-		4,230
Total assets measured at fair value	$	22,440	$	8,932	$	-	$	31,372


		Fair Value Measurements at Reporting Date Using
December 31, 2011		Quoted Prices in Active Markets for identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
(In thousands of U.S. dollars)		(Level 1)		(Level 2)		(Level 3)		Total
U.S. government securities	$	-	$	4,248	$	-	$	4,248
U.S. commercial paper		-		2,000		-		2,000
Corporate bonds		-		7,007		-		7,007
Money market funds		12,885		-		-		12,885
Variable rate demand notes		-		12,195		-		12,195
Total assets measured at fair value	$	12,885	$	25,450	$	-	$	38,335

If quoted prices in active markets for identical assets and liabilities are not available to determine fair value, then the Company uses quoted prices for similar assets and liabilities or inputs other than the quoted prices that are observable, either directly or indirectly. This pricing methodology applies to the Company’s Level 2 investments.

Intangible Assets	9 Months Ended
Intangible Assets	Sep. 30, 2012
Intangible Assets [Abstract]
Intangible Assets	5.Intangible Assets In April 2009, the Company entered into an agreement with R-Tech, or the 2009 R-Tech Agreement, to acquire all patents and other intellectual property rights related to RESCULA for its FDA approved indication and any new indications for unoprostone isopropyl in the U.S. and Canada. Although RESCULA eye drops have been approved by the FDA since 2000, RESCULA is not currently marketed in the U.S. or Canada. The Company plans to launch RESCULA in the U.S. shortly after the approval of the sNDA. Under the terms of the 2009 R-Tech Agreement, the Company made an upfront payment of $3.0 million and may be required to pay up to $5.5 million in additional milestone payments to R-Tech based on the achievement of specified development and commercialization goals. The first milestone payment of $500,000 is payable upon the launch of RESCULA for the treatment of is approved for the treatment of the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension which is considered as being probable; therefore, this amount is recorded as part of the initial cost of the acquired assets. The Company allocated the acquisition cost between an intangible asset of $3.4 million and a non-current prepaid inventory of $85,000 as of December 31, 2011, both of which are reflected in other non-current assets in the accompanying Condensed Consolidated Balance Sheets. The cost is amortized over the 10-year life of the 2009 R-Tech Agreement, which the Company believes approximates the useful life of the underlying rights and data. Amortization expense was approximately $85,000 for the three months ended September 30, 2012 and 2011, respectively, and approximately $256,000 for the nine months ended September 30, 2012 and 2011, respectively. The annual amortization expense will be approximately $341,000 through April 2019. On March 22, 2011, the Company entered into a license agreement with R-Tech for unoprostone isopropyl, or the 2011 R-Tech Agreement, expanding the Company’s development and commercialization rights as well as its territories beyond their previously agreed territory of the United States and Canada to the rest of the world, with the exception of Japan, Korea, Taiwan and the People’s Republic of China. The Company is now evaluating the opportunities to obtain an appropriate label in the E.U. and other European countries, and the timing of seeking reauthorization in those countries to commercialize unoprostone isopropyl. The Company has made payments to R-Tech of $6.0 million, which is reflected in other non-current assets in the accompanying Condensed Consolidated Balance Sheets, and may be required to pay up to $100.0 million in additional milestone payments to R-Tech based on the achievement of specified development and commercialization goals. Sucampo AG, or SAG, will be responsible for all development, regulatory, and commercialization activities. The Company is amortizing the $6.0 million over the 10-year life of the license agreement, which the Company believes approximates the useful life of the underlying rights and data. Amortization expense was approximately $153,000 for the three months ended September 30, 2012 September 30, 2011 and approximately $460,000 and $300,000 for the nine months ended September 30, 2012 and 2011, respectively. The annual amortization expense will be approximately $613,000 through March 2021.

Accrued Expenses

9 Months Ended

Sep. 30, 2012

Accrued Expenses [Abstract]

Accrued Expenses

6.Accrued Expenses

Accrued expenses consist of the following as of:


		September 30,		December 31,
(In thousands of U.S. dollars)		2012		2011
Research and development costs	$	3,446	$	5,622
Employee compensation		2,536		1,607
Selling and marketing costs		340		76
Legal service fees		732		1,955
RESCULA milestone		500		3,500
Other accrued expenses		1,246		888
Total	$	8,800	$	13,648

Commitments

9 Months Ended

Sep. 30, 2012

Commitments [Abstract]

Commitments

7.Commitments

Operating Leases

The Company leases office space in the U.S., Switzerland, Japan and U.K., under operating leases through 2017. Total future minimum, non-cancelable lease payments under operating leases, are as follows as of September 30, 2012:


(In thousands of U.S. dollars)
2012 (October - December)	$	412
2013		1,103
2014		1,024
2015		1,052
2016		1,084
2017 and thereafter		139
Total minimum lease payments	$	4,814

Rent expense for all operating leases was approximately $426,000 and $376,000 for the three months ended September 30, 2012 and 2011, respectively, and $1.2 million and $1.1 for the nine months ended September 30, 2012 and 2011, respectively.

Research and Development Costs

The Company routinely enters into agreements with third-party contract research organization to oversee clinical research and development studies provided on an outsourced basis and assist in other research and development activities. The Company generally is not contractually obligated to pay the third party if the service or reports are not provided. Total future estimated costs through 2012 under these agreements as of September 30, 2012 were approximately $5.0 million.

Related Party Transactions

9 Months Ended

Sep. 30, 2012

Related Party Transactions

8.Related Party Transactions

R-Tech Ueno, Ltd.

In addition to the unoprostone isopropyl agreements described in Note 5 above, the Company is a party to other development and exclusive supply agreements with R-Tech covering various compounds and territories. The Company’s founders, Drs. Ryuji Ueno and Sachiko Kuno, directly or indirectly, own a majority of the stock of R-Tech.

The Company recorded the following expenses under its agreements with R-Tech for the three and nine months ended September 30, 2012 and 2011:


		Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands of U.S. dollars)		2012		2011		2012		2011
Clinical supplies	$	331	$	-	$	1,618	$	-
Other research and development services		147		93		451		100
Commercial supplies		298		21		443		144
	$	776	$	114	$	2,512	$	244

The following table summarizes the amounts included in deferred revenue resulting from the deferral of upfront payments relating to the exclusive supply agreements with R-Tech as of September 30, 2012 and December 31, 2011:


		September 30,		December 31,
(In thousands of U.S. dollars)		2012		2011
Deferred revenue, current	$	464	$	433
Deferred revenue, non-current		5,274		5,063
	$	5,738	$	5,496

The Company recognized approximately $112,000 and $105,000 of revenue relating to its agreements with R-Tech for each of the three months ended September 30, 2012 and 2011, and approximately $321,000 and $314,000 for the nine months ended September 30, 2012 and 2011, respectively, which was recorded as contract and collaboration revenue in the accompanying Condensed Consolidated Statements of Operations and Comprehensive Income (Loss). The increase in deferred revenue for the nine months ended September 30, 2012 includes a $500,000 milestone receivable from R-Tech as a result of the AMITIZA June NDA approval in Japan.

Numab AG

In September 2011, the Company entered into a Loan Guarantee and Development Agreement, or Numab Agreement, with Numab. Numab is considered a related party as a result of an ownership interest by one of the Company’s executive officers. Under the terms of the Numab Agreement, the Company will provide Numab with up to CHF 5.0 million, approximately $5.2 million as of the closing date, as collateral and will serve as guarantor for a loan to Numab from a third party. The Company may name up to four targets against which Numab will use their proprietary technology to discover high-affinity antibodies and to develop these to an investigational new drug ready stage. Numab is eligible for full time equivalent based payments and discovery success dependent fees. Any success dependent fees will result in a corresponding reduction in the amount of the available guarantee. Should Numab default its loan obligations, the collateral may be called upon to meet Numab’s obligation under its loan agreement. As of September 30, 2012, the collateral of $3.3 million has been deposited by the Company and Numab has utilized CHF 3.0 million of its 5.0 million loan. In reviewing the amount outstanding of the loan, the Company has recorded a liability of $1.2 million in collateral callable to meet a potential loan default by Numab. If a biologic is successfully developed, Numab and the Company may enter into a license arrangement in which Numab will be entitled to clinical development milestone payments and increasing tiered royalties on net sales. The Company will be responsible for clinical development and will retain all commercial rights to any resulting biologic product.

In February 2012, the Company entered into a Master Lease Agreement, or Lease Agreement, with Numab whereby the maximum collateral of CHF 5.0 million is reduced by the purchase cost of any equipment leased to Numab. As of September 30, 2012, equipment with a purchase cost of CHF 544,000, approximately $570,000 as of the closing date, was leased to Numab thus reducing the maximum collateral and loan guarantee to CHF 4.5 million. Monthly rental payments are received under the terms of the lease.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph b
-Article 3A

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph k
-Article 4

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 57
-Paragraph 1-4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Notes Payable

9 Months Ended

Sep. 30, 2012

Notes Payable [Abstract]

Notes Payable

9.Notes Payable

In November 2010, SPL entered into a ¥1,000,000,000, approximating $12.8 million as of the closing date, secured term loan agreement with The Bank of Tokyo-Mitsubishi UFJ, Ltd, or the Bank. The loan agreement provides for the extension of credit for the period of one year that can be renewed annually upon the agreement of the Company, SPL and the Bank. The loan was renewed in November 2011. Borrowings may be used to finance research and development activities, for working capital needs and for the general corporate purposes of SPL. The loan bears annual interest based on the three-month Tokyo Interbank Offer Rate, plus 1% and is reset quarterly. The interest rate at September 30, 2012 was 1.24%. The outstanding loan balances included in the accompanying Condensed Consolidated Balance Sheets were $12.8 million and $12.9 million as of September 30, 2012 and December 31, 2011. In connection with the loan agreement, the Company and the Bank executed a guarantee agreement which provides a full guarantee by the Company on behalf of SPL’s obligation to the Bank. The loan agreement includes representations, covenants, and events of default customary for financing transactions of this type. Additionally, the Company agreed to maintain an amount of collateral that would not fall below 90.0% of the initial balance throughout the term of the loan. The Company deposited $14.9 million with the Bank and the deposit bears annual interest of 0.4%, which is recorded as restricted cash, current in the accompanying Condensed Consolidated Balance Sheets as of September 30, 2012 and December 31, 2011.

Subordinated Unsecured Promissory Notes

In connection with the acquisition of SAG and its wholly owned subsidiary SAG-J in December 2010, Ambrent Investments S.à r.l., or Ambrent, issued a subordinated unsecured promissory note, or notes, to each of the Ueno Trust and Kuno Trust, each a related party. Each of the notes was issued with an initial principal balance of approximately $25.9 million, or approximately $51.9 million in the aggregate. The interest rate for the notes is equal to the per annum rate of interest determined on the basis of the sum of London Interbank Offered Rate, plus 4.0%, and is reset every six months on December 1st and June 1st of each year. The interest rate beginning June 1, 2012 is 4.7%.

The notes provide for annual payments of the first two payments on December 31, 2011 and 2012, respectively, and then for a semi-annual payment schedule of interest and principal over a seven-year period on each June 1st and December 1st, provided that, until December 1, 2012 all accrued and unpaid interest will not be paid in cash but instead added to the principal balance of the notes. Ambrent made one principal payment on December 1, 2011 and is scheduled to make the next principal payment on December 1, 2012. For the nine months ended September 30, 2012, approximately $1.7 million of interest expense was added to the principal balance of the notes as paid-in-kind.

The notes can be prepaid at any time without penalty. In addition, the notes provide for a mandatory prepayment (i) in full in the event of an acquisition by an unaffiliated third party in an all-cash acquisition of all of the issued and outstanding shares of capital stock of the Company or (ii) either in full or in part in certain change of control transactions involving the Company where an unaffiliated third party acquires a majority of the Company’s voting stock.

Notes payable consist of the following as of September 30, 2012 and December 30, 2011:


		September 30,		December 31,
(In thousands of U.S. dollars)		2012		2011
Loan agreement, The Bank of Tokyo-Mitsubishi UFJ, Ltd	$	12,800	$	12,900
Promissory notes, Sellers of SAG		48,383		46,727
	$	61,183	$	59,627

Notes payable, current	$	20,300	$	20,400
Notes payable, non-current		40,883		39,227
	$	61,183	$	59,627

The aggregated scheduled maturities of notes payable were as follows as of September 30, 2012:

SUCAMPO PHARMACEUTICALS, INC.

Notes to Condensed Consolidated Financial Statements (Unaudited) - (Continued)


		September 30,
		2012
(In thousands)
Due in one year	$	20,300
Due in two years		8,837
Due in three years		8,938
Due in four years		9,045
Due in five years		9,156
Thereafter		4,907
	$	61,183

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References + Details

Collaboration And License Agreements

9 Months Ended

Sep. 30, 2012

Collaboration And License Agreements [Abstract]

Collaboration And License Agreements

10.Collaboration and License Agreements

Abbott Agreement

In February 2009, the Company entered into the Abbott Agreement to develop and commercialize lubiprostone for the treatment of CIC in Japan. Additionally, the Abbott Agreement grants Abbott the right to a limited time period of exclusive negotiation to any other indications for which lubiprostone is developed in Japan under all relevant patents, know-how and trademarks. Under the terms of the Abbott Agreement, payments to the Company include a non-refundable upfront payment and non-refundable development and commercial milestone payments based on achieving specified development, regulatory and sales goals.

To date, the Company has received a total of $22.5 million in upfront and development milestone payments under Abbott Agreement, including a $5.0 million development milestone payment, received in October 2010, for the submission of a marketing application to the PMDA for lubiprostone at a dosage strength of 24 micrograms for the indication of CIC in Japanese adults, as well as $10.0 million and $7.5 million in upfront and development milestone payments, respectively, in 2009. Under the Abbott Agreement the Company could receive additional milestone payments based on achieving other specified development and commercialization goals, including $15.0 million due on the first commercial sale in Japan, although there can be no assurance that the Company will receive any such payments.

The following table summarizes the cash streams and related revenue recognized or deferred under the Abbott Agreement for the nine months ended September 30, 2012:


		Amount Deferred at December 31,		Cash Received for the Nine Months Ended September 30,		Revenue Recognized for the Nine Months Ended September 30,		Foreign Currency Effects for the Nine Months Ended September 30,		Amount Deferred at September 30,
(In thousands of U.S. dollars)		2011		2012		2012		2012		2012
Collaboration revenue:
Up-front payment associated with the Company's
obligation to participate in joint committees	$	860	$	-	$	39	$	(7)	$	814

Research and development revenue:
Up-front payment	$	203	$	-	$	199	$	(4)	$	-
Development milestone payment		273		-		267		(6)	$	-
Total	$	476	$	-	$	466	$	(10)	$	-

Takeda commercialization and license agreement

The Company has received a total of $150.0 million in upfront and development milestone payments through September 30, 2012 under the Takeda Agreement. Subject to future development and commercial milestones, the Company is potentially entitled to receive additional development milestone and commercial milestone payments under the Takeda Agreement, although there can be no assurance that the Company will receive any such payments.

The following table summarizes the cash streams and related revenue recognized or deferred under the Takeda Agreements for the three and nine months ended September 30, 2012:


		Amount Deferred at December 31,		Cash Received for the Nine Months Ended September 30,		Revenue Recognized for the Nine Months Ended September 30,		Change in Accounts Receivable for the Nine Months Ended September 30,		Amount Deferred at September 30,
(In thousands of U.S. dollars)		2011		2012		2012		2012*		2012
Collaboration revenue:
Up-front payment associated with the Company's
obligation to participate in joint committees	$	1,323	$	-	$	110	$	-	$	1,213

Research and development revenue:
Reimbursement of research and development expenses	$	2,778	$	10,884	$	5,952	$	(4,533)	$	3,177

Product royalty revenue	$	-	$	35,614	$	36,521	$	907	$	-

Co-promotion revenue	$	-	$	3,407	$	3,253	$	(154)	$	-

* Includes billed and unbilled accounts receivable.

Stock Option Plans

9 Months Ended

Sep. 30, 2012

Stock Options Plans [Abstract]

Stock Option Plans

11.Stock Option Plans

The following table summarizes the employee stock option activity for the nine months ended September 30, 2012 under the Company’s 2001 Incentive Plan:


	Shares		Weighted Average Exercise Price Per Share	Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Options outstanding, December 31, 2011	190,400	$	10.00
Options expired	(34,000)		10.00
Options outstanding, September 30, 2012	156,400		10.00	3.59	$	-
Options exercisable, September 30, 2012	156,400		10.00	3.59	$	-

The following table summarizes the employee stock option activity for the three and six months ended June 30, 2012 under the Company’s Amended and Restated 2006 Stock Incentive Plan:


	Shares		Weighted Average Exercise Price Per Share	Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Options outstanding, December 31, 2011	3,402,380	$	4.75
Options granted	428,850		6.53
Options exercised	(17,484)		3.86
Options forfeited	(380,870)		4.53
Options expired	(11,164)		11.21
Options outstanding, September 30, 2012	3,421,712		4.98	8.12	$	2,301,889
Options exercisable, September 30, 2012	881,407		6.01	6.25	$	616,952

The weighted average grant date fair value of options awarded during the nine months ended September 30, 2012 and the year ended December 31, 2011 was $6.53 and $1.81, respectively. As of September 30, 2012, approximately $2.6 million of total unrecognized compensation costs, net of estimated forfeitures, related to non-vested awards are expected to be recognized over a weighted average period of 2.46 years.

The Company granted 510,000 stock options with an exercise price of $5.85 per share to non-employees in August 2005 under the Company’s 2001 Incentive Plan. As of September 30, 2012 and December 31, 2011, 450,000 of these options were outstanding and exercisable. These non-employee stock options vested immediately and have a weighted average exercise price per share of $5.85 and $5.85, respectively, and remaining contractual life of 2.59 and 3.33 years, respectively, as of September 30, 2012 and December 31, 2011.

Employee Stock Purchase Plan

Under the Company’s 2006 Employee Stock Purchase Plan, or ESPP, a total of 2,471 and 2,136 shares of class A common stock were purchased during the nine months ended September 30, 2012 and 2011, respectively. The ESPP is non-compensatory and is intended to qualify as an Employee Stock Purchase Plan as defined in Section 423 of the Internal Revenue Code of 1986, as amended, and in accordance with GAAP guidance that requires estimates in the fair value of share-based payment awards on the date of the grant using an option-pricing model and recognizing the expense over the required service periods in the accompanying Condensed Consolidated Statement of Operations and Comprehensive Income (Loss). The Company received $15,266 and $8,133 upon purchase of shares under the ESPP for the nine months ended September 30, 2012 and 2011, respectively.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64, 65, A240
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 93-6
-Paragraph 53
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2012
Income Taxes [Abstract]
Income Taxes	12.Income Taxes The Company has estimated its annual effective tax rate for the full fiscal year 2012 and 2011 and applied that rate to its income before income taxes in determining its income tax provision for the interim periods. Non-recurring and discrete items that impact tax expense are recorded in the period incurred. For the three months ended September 30, 2012 and 2011, the Company recorded a tax provision of $3.8 million and $196,000, respectively. For the nine months ended September 30, 2012 and 2011, the Company recorded a tax provision of $3.1 million and a tax benefit of $5.0 million, respectively. The tax provision for the three months ended September 30, 2012 primarily pertained to pre-tax profits generated by the Company’s U.S and Japanese subsidiaries and a net discrete benefit of $557,000, which is discussed below. The tax provision for the nine months ended September 30, 2012 primarily pertained to a tax expense on pre-tax profits and losses generated by the Company’s U.S. and Japanese subsidiaries, offset by a net discrete benefit of $1.3 million, which is discussed below. The discrete items for the three months were primarily related to: (i) a benefit of $812,000 from return to provision adjustments, primarily related to a redetermination of profits and losses earned in various jurisdictions (as a result of the intellectual property transfer changes discussed below); and (ii) additional expense of $185,000 related to amortization of the deferred charge and interest for the intellectual property transferred to SAG (other than the U.S. rights related to AMITIZA). The discrete items for the nine months related primarily to the items noted above, plus (i) a benefit of $778 thousand related to the second quarter intellectual property transfer adjustment discussed below; (ii) an additional benefit of $351,000 related to the second quarter settlement of a tax audit and changes to the estimated liability for uncertain tax positions (see further discussion below); (iii) additional expense of $372,000 related to the amortization of the deferred charge and interest for the intellectual property transferred to SAG (other than the U.S. rights related to AMITIZA); and (iv) a tax expense of $158,000 related to stock option forfeitures. In September 2011, the Company internally transferred certain intellectual property and licenses from the Company’s subsidiaries including the U.S. based subsidiary to SAG. Following the decision of the International Court of Arbitration of the International Chamber of Commerce on the Takeda Agreement in July 2012, the Company has determined that the internal transfer of the intellectual property is partially complete, but the Company continues to evaluate whether the U.S. rights to related to AMITIZA will transfer to SAG in the future. This resulted in a reassessment of the deferred charge, deferred tax liability and the mix of profits and losses earned in each jurisdiction. In the second quarter of 2012, the Company recorded a discrete benefit of approximately $778,000. In addition, the Company discretely reduced the deferred charge and deferred tax liability by approximately $23.8 million and $24.1 million, respectively for the three and nine months ended September 30, 2012. Management is actively working to complete the internal transfer of the remaining intellectual property, which could occur in 2012. An additional deferred charge will be recorded in the period in which the transfer is completed. Uncertain Tax Positions The Company applies the relevant guidance for uncertainty in income taxes that requires the application of a more likely than not threshold to the recognition and derecognition of uncertain tax positions. The Company had an outstanding non-current income tax liability of approximately $1.2 million, including interest, for uncertain tax positions as of September 30, 2012. The amount represented the aggregate tax effect of differences between tax return positions and the amounts otherwise recognized in the Company’s Condensed Consolidated Financial Statements, and is reflected in other liabilities in the accompanying Condensed Consolidated Balance Sheets. The liability for uncertain tax positions as of September 30, 2012 mainly pertained to the Company’s interpretation of nexus in certain states related to revenue sourcing for state income tax purposes. During the nine months ended September 2012, the liability for income taxes has decreased approximately $283,000. This decrease in the liability is primarily related to the settlement of a tax audit in Japan offset by an increase related to current year activity in the U.S. including settlements with tax authorities and revisions to prior year’s estimates. As a result of these changes to the uncertain tax liability, a discrete provision of approximately $84,000 and benefit of approximately $268,000, respectively, was recorded in the three months and nine months ended September 30, 2012. The Company recognizes accrued interest and penalties related to uncertain tax positions as a component of the income tax provision. The Company has identified no uncertain tax position for which it is reasonably possible that the total amount of liability for unrecognized tax benefits will significantly increase or decrease within 12 months, except for recurring accruals on existing uncertain tax positions.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 136, 172
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 43, 44, 45, 46, 47, 48, 49
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Segment Reporting

9 Months Ended

Sep. 30, 2012

Segment Reporting [Abstract]

Segment Reporting

13. Segment Reporting

The Company has determined that it has three reportable segments based on the Company’s method of internal reporting, which disaggregates business by geographic location. These segments are the Americas, Europe and Asia. The Company evaluates the performance of these segments based on income (loss) from operations, as well as other factors, that depend on the development status of these geographies. Such measures include the progress of its research and development activities, collaboration and licensing efforts, commercialization activities and other factors. The reportable segments have historically derived their revenue from joint collaboration and strategic alliance agreements. Transactions between the segments consist primarily of loans and the provision of research and development services. Following is a summary of financial information by reportable geographic segment:


(In thousands of U.S. dollars)		Americas		Europe		Asia		Consolidated
Three Months Ended September 30, 2012
Research and development revenue	$	665	$	72	$	-	$	737
Product royalty revenue		13,890		-		-		13,890
Co-promotion revenue		730		-		-		730
Contract and collaboration revenue		141		(15)		13		139
Total revenues		15,426		57		13		15,496
Research and development expenses		2,239		2,543		833		5,615
Depreciation and amortization		122		242		10		374
Other operating expenses		9,677		1,161		322		11,160
Income (loss) from operations		3,388		(3,889)		(1,152)		(1,653)
Interest income		65		3		-		68
Interest expense		-		(556)		(40)		(596)
Other non-operating expense		34		165		(191)		8
Loss before income taxes	$	3,487	$	(4,277)	$	(1,383)	$	(2,173)
Capital expenditures	$	41	$	-	$	-	$	41

Three Months Ended September 30, 2011
Research and development revenue	$	2,658	$	-	$	227	$	2,885
Product royalty revenue		10,563		-		-		10,563
Co-promotion revenue		769		-		-		769
Contract and collaboration revenue		141		-		14		155
Total revenues		14,131		-		241		14,372
Research and development expenses		6,552		965		1,208		8,725
Depreciation and amortization		215		167		(6)		376
Other operating expenses		9,014		403		376		9,793
Loss from operations		(1,650)		(1,535)		(1,337)		(4,522)
Interest income		32		2		1		35
Interest expense		-		(576)		(43)		(619)
Other non-operating income (expense), net		(10)		1,463		(229)		1,224
Loss before income taxes	$	(1,628)	$	(646)	$	(1,608)	$	(3,882)
Capital expenditures	$	15	$	3	$	86	$	104


(In thousands)		Americas		Europe		Asia		Consolidated
Nine Months Ended September 30, 2012
Research and development revenue	$	5,878	$	74	$	466	$	6,418
Product royalty revenue		36,521		-		-		36,521
Co-promotion revenue		3,253		-		-		3,253
Contract and collaboration revenue		424		(30)		39		433
Total revenues		46,076		44		505		46,625
Research and development expenses		6,250		5,405		2,547		14,202
Depreciation and amortization		366		709		30		1,105
Other operating expenses		32,475		2,576		916		35,967
Income (loss) from operations		6,985		(8,646)		(2,988)		(4,649)
Interest income		105		12		1		118
Interest expense		-		(1,656)		(124)		(1,780)
Other non-operating expense		67		82		578		727
Loss before income taxes	$	7,157	$	(10,208)	$	(2,533)	$	(5,584)
Capital expenditures	$	293	$	3,445	$	-	$	3,738

Nine Months Ended September 30, 2011
Research and development revenue	$	5,555	$	-	$	1,036	$	6,591
Product royalty revenue		30,724		-		-		30,724
Co-promotion revenue		2,768		-		-		2,768
Contract and collaboration revenue		424		-		39		463
Total revenues		39,471		-		1,075		40,546
Research and development expenses		19,465		2,352		4,021		25,838
Depreciation and amortization		668		325		33		1,026
Other operating expenses		33,232		807		941		34,980
Loss from operations		(13,894)		(3,484)		(3,920)		(21,298)
Interest income		155		3		2		160
Interest expense		-		(1,719)		(125)		(1,844)
Other non-operating income (expense), net		(21)		(1,779)		(233)		(2,033)
Loss before income taxes	$	(13,760)	$	(6,979)	$	(4,276)	$	(25,015)
Capital expenditures	$	93	$	6,003	$	188	$	6,284


As of September 30, 2012
Property and equipment, net	$	1,287	$	15	$	261	$	1,563
Identifiable assets, net of intercompany loans
and investments	$	95,849	$	14,507	$	10,775	$	121,131

As of December 31, 2011
Property and equipment, net	$	1,359	$	16	$	294	$	1,669
Identifiable assets, net of intercompany loans
and investments	$	96,490	$	47,925	$	13,154	$	157,569

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Summary Of Significant Accounting Policies (Policy)	9 Months Ended
Summary Of Significant Accounting Policies (Policy)	Sep. 30, 2012
Summary Of Significant Accounting Policies [Abstract]
Cash And Cash Equivalents	Cash and Cash Equivalents For the purpose of the Condensed Consolidated Balance Sheets and Statements of Cash Flows, cash equivalents include all highly liquid investments with a maturity of 90 days or less at the time of purchase.
Restricted Cash	Restricted Cash Restricted cash consists of approximately $18.7 million and 17.2 million at September 30, 2012 and December 31, 2011, respectively. Restricted cash represents cash required to be deposited with certain financial institutions in connection with the Sucampo Pharma, Ltd., or SPL, loan agreement with The Bank of Tokyo-Mitsubishi UFJ, Ltd., Numab’s loan agreement with Zurcher Kantonalbank and operating leases.
Current And Non-current Investments	Current and Non-current Investments Current and non-current investments consist primarily of U.S. government agencies securities, corporate bonds, mutual funds and variable rate demand notes. The Company classifies its investments into current and non-current based on their maturities and management’s reasonable expectation to realize these investments in cash. The Company classifies all of its investments as available for sale securities and reports unrealized gains or losses, net of related tax effects, in other comprehensive income.
Fair Value Of Financial Instruments	Fair Value of Financial Instruments The carrying amounts of the Company’s financial instruments, which include cash and cash equivalents, restricted cash, current and non-current investments, receivables, accounts payable and accrued expenses, approximate their fair values based on their short maturities, independent valuations or internal assessments. The carrying amount of the short and long-term debt at September 30, 2012 and December 31, 2011 approximated its fair value due to the fact that the interest rates are determined based by reference to interbank rates. The Company’s debt is subject to the fair value disclosure requirements as discussed in Note 4 below, is considered a Level 2 security.
Accounts Receivable And Unbilled Accounts Receivable	Accounts Receivable and Unbilled Accounts Receivable Accounts receivable represent mainly amounts due under the Takeda and the Abbott Agreements. Unbilled accounts receivable represent the research and development expenses that are reimbursable by Takeda but have not been billed to Takeda as of the balance sheet date. The Company recorded an allowance for doubtful accounts at September 30, 2012 of approximately $192,000 related to certain disputed Takeda invoices. No allowance was recorded in 2011.
Product Royalties Receivable	Product Royalties Receivable Product royalties receivable represent amounts due from Takeda for the Company’s royalties on sales of AMITIZA, which are based on reports obtained directly from Takeda.
Revenue Recognition	Revenue Recognition The Company’s revenues are derived primarily from collaboration and license agreements and include upfront payments, development milestone payments, reimbursements of development and co-promotion costs and product royalties. The Company evaluated the multiple deliverables within the collaboration and license agreements in accordance with the guidance of multiple deliverables to determine whether the delivered elements that are the obligation of the Company have value to other parties to the agreement on a stand-alone basis and whether objective reliable evidence of fair value of the undelivered items exists. Deliverables that meet these criteria are considered a separate unit of accounting. Deliverables that do not meet these criteria are combined and accounted for as a single unit of accounting. The appropriate recognition of revenue is then applied to each separate unit of accounting. Royalty revenues are based on net sales of licensed products and are recorded on the accrual basis when earned in accordance with contractual terms when third-party results are reliably measurable, collectability is reasonably assured and all other revenue recognition criteria are met. Collaboration revenues relate to reimbursements of co-promotion costs based upon a rate per detail and reimbursements of the costs of miscellaneous marketing activities. The Company considers its participation in the joint committees under the collaboration and license agreements as separate deliverables under the contracts and recognizes the fair value of such participation as collaboration revenue over the period of the participation per the terms of the contracts. The Company has determined that it is acting as a principal under both the Takeda Agreement and Abbott Agreement and, as such, records revenue on a gross basis in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss). Contract Revenue Contract revenue relates to development and consulting activities and is accounted for under the time-based model.
Certain Risks, Concentrations And Uncertainties	Certain Risks, Concentrations and Uncertainties Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents, restricted cash, investments and receivables. The Company places its cash, cash equivalents and restricted cash with highly rated financial institutions and invests its excess cash in highly rated investments. As of September 30, 2012 and December 31, 2011, approximately $4.6 million, or 5.6%, and $15.6 million, or 16.7%, respectively, of the Company’s cash, cash equivalents, restricted cash and investments were issued or insured by the federal government or government agencies. The Company has not experienced any losses on these accounts related to amounts in excess of insured limits. The Company’s products and product candidates under development require approval from the FDA or other international regulatory agencies prior to commercial sales. For those product candidates or indications that have not yet been approved by the FDA or international regulatory agencies, there can be no assurance the products will receive the necessary approval. If the Company is denied approval or approval is delayed, it may have a material adverse impact on the Company. The Company’s products, AMITIZA and RESCULA, compete in a rapidly changing, highly competitive market, which is characterized by advances in scientific discovery, changes in customer requirements, evolving regulatory requirements and developing industry standards. Any failure by the Company to anticipate or to respond adequately or timely to scientific developments in its industry, changes in customer requirements or changes in regulatory requirements or industry standards, or any significant delays in the development or introduction of products could have a material adverse effect on the Company’s business, operating results and future cash flows. The Company’s expected activities may necessitate significant uses of working capital. The Company’s working capital requirements will depend on many factors, including the successful sales of AMITIZA and RESCULA, research and development efforts to develop new products or indications, payments received under contractual agreements with other parties, the status of competitive products and market acceptance of the Company’s new products by physicians and patients. The Company plans to continue financing operations with its existing cash and investments as well as with product royalty revenue and cash received from milestones and other revenue related to its joint collaboration, license and supply agreements. Revenues from one unrelated party, Takeda, accounted for 98.7% and 97.6%, of the Company’s total revenues for the three months ended September 30, 2012 and 2011, respectively, and 98.0% and 96.6% for the nine months ended September 30, 2012 and 2011, respectively. Accounts receivable, unbilled accounts receivable and product royalties receivable from Takeda accounted for 96.0% and 100.0% of the Company’s total accounts receivable, unbilled accounts receivable and product royalties receivable at September 30, 2012 and December 31, 2011, respectively. Revenues from another unrelated party, Abbott, accounted for 0.1% and 1.7% of the Company’s total revenues for the three months ended September 30, 2012 and 2011, respectively, and 1.1% and 2.7% for the nine months ended September 30, 2012 and 2011, respectively. The Company depends significantly upon the collaborations with Takeda and Abbott and its activities may be impacted if these relationships are disrupted. The Company has an exclusive supply arrangement with R-Tech to provide it with commercial and clinical supplies of its product and product candidates. R-Tech also provides certain preclinical and other research and development services. Any difficulties or delays in performing the services under these arrangements may cause the Company to lose revenues, delay research and development activities or otherwise disrupt the Company’s operations.

- Definition

Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 305
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2122427

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Financial Reporting Release (FRR)
-Number 203
-Paragraph 02-03

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 1
-Article 5

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Technical Practice Aid (TPA)
-Number 2110
-Paragraph 6
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7, 8, 9, 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.

+ References + Details

- Definition

Disclosure of accounting policy for credit risk.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 55
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6875567&loc=d3e14489-108613

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 825
-Section 55
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6487554&loc=d3e32600-158583

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 825
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6480020&loc=d3e61082-112788

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13531-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 55
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6875567&loc=d3e14537-108613

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 825
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6480020&loc=d3e61044-112788

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number SOP94-6-1
-Paragraph 7, 11
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 113
-Paragraph 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 01-6
-Paragraph 14
-Subparagraph m
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=6382943&loc=d3e33918-111571

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27290-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.2,12)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 325
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6872867&loc=d3e40691-111596

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section M

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 7-18
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 2, 12
-Article 5

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 7-16
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 10, 11
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References + Details

Earnings Per Share (Tables)

9 Months Ended

Sep. 30, 2012

Earnings Per Share [Abstract]

Computation Of Net Income (Loss) Per Share



		Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands of U.S. dollars, except per share data)		2012		2011		2012		2011
Basic net loss per share:
Net loss	$	(5,949)	$	(4,078)	$	(8,696)	$	(20,006)

Weighted average class A and B common shares
outstanding		41,678		41,877		41,697		41,864

Basic net loss per share		(0.14)		(0.10)		(0.21)		(0.48)

Diluted net loss per share:
Net loss	$	(5,949)	$	(4,078)	$	(8,696)	$	(20,006)

Weighted average class A and B common shares
outstanding for diluted net income per share		41,678		41,877		41,697		41,864

Diluted net loss per share		(0.14)		(0.10)		(0.21)		(0.48)

Securities Excluded From Computation Of Diluted Net Loss Per Share


	September 30,
(In thousands of U.S. dollars)	2012	2011
Employee stock options	3,578	3,427
Non-employee stock options	450	450

Current And Non-Current Investments (Tables)

9 Months Ended

Sep. 30, 2012

Current And Non-Current Investments [Abstract]

Current And Non-Current Available-For-Sale Investments


		September 30, 2012
				Unrealized		Unrealized
(In thousands of U.S. dollars)		Cost		Gains		Losses		Fair Value
Current:
U.S. commercial paper	$	1,999	$	-	$	-	$	1,999
Municipal securities		4,230		-		-		4,230
Total	$	6,229	$	-	$	-	$	6,229

		December 31, 2011
				Unrealized		Unrealized
(In thousands of U.S. dollars)		Cost		Gains		Losses		Fair Value
Current:
U.S. commercial paper	$	1,997	$	3	$	-	$	2,000
U.S. government securities		3,250		-		-		3,250
Corporate bonds		7,002		8		(3)		7,007
Variable rate demand notes		12,195		-		-		12,195
Total	$	24,444	$	11	$	(3)	$	24,452

Non-current:
U.S. government securities	$	1,000	$	-	$	(2)	$	998
Total	$	1,000	$	-	$	(2)	$	998

Company's Assets Measured At Fair Value On Recurring Basis


		Fair Value Measurements at Reporting Date Using
September 30, 2012		Quoted Prices in Active Markets for identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
(In thousands of U.S. dollars)		(Level 1)		(Level 2)		(Level 3)		Total
U.S. government securities	$	-	$	-	$	-	$	-
U.S. commercial paper		-		3,499		-		3,499
Corporate bonds		-		1,203		-		1,203
Money market funds		22,440		-		-		22,440
Variable rate demand notes		-		4,230		-		4,230
Total assets measured at fair value	$	22,440	$	8,932	$	-	$	31,372


		Fair Value Measurements at Reporting Date Using
December 31, 2011		Quoted Prices in Active Markets for identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
(In thousands of U.S. dollars)		(Level 1)		(Level 2)		(Level 3)		Total
U.S. government securities	$	-	$	4,248	$	-	$	4,248
U.S. commercial paper		-		2,000		-		2,000
Corporate bonds		-		7,007		-		7,007
Money market funds		12,885		-		-		12,885
Variable rate demand notes		-		12,195		-		12,195
Total assets measured at fair value	$	12,885	$	25,450	$	-	$	38,335

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27337-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27198-111563

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27161-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27357-111563

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27290-111563

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 19, 20, 21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 17
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 03-1
-Paragraph 21
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).

+ References + Details

Accrued Expenses (Tables)

9 Months Ended

Sep. 30, 2012

Accrued Expenses [Abstract]

Schedule Of Accrued Expenses


		September 30,		December 31,
(In thousands of U.S. dollars)		2012		2011
Research and development costs	$	3,446	$	5,622
Employee compensation		2,536		1,607
Selling and marketing costs		340		76
Legal service fees		732		1,955
RESCULA milestone		500		3,500
Other accrued expenses		1,246		888
Total	$	8,800	$	13,648

Commitments (Tables)

9 Months Ended

Sep. 30, 2012

Commitments [Abstract]

Future Minimum, Non-Cancelable Lease Payments Under Operating Leases


(In thousands of U.S. dollars)
2012 (October - December)	$	412
2013		1,103
2014		1,024
2015		1,052
2016		1,084
2017 and thereafter		139
Total minimum lease payments	$	4,814

Related Party Transactions (Tables)

9 Months Ended

Sep. 30, 2012

Expenses Under Agreements With R-Tech


		Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands of U.S. dollars)		2012		2011		2012		2011
Clinical supplies	$	331	$	-	$	1,618	$	-
Other research and development services		147		93		451		100
Commercial supplies		298		21		443		144
	$	776	$	114	$	2,512	$	244

Amounts Included In Deferred Revenue Resulting From Deferral Of Upfront Payments Relating To Exclusive Supply Agreements With R-Tech


		September 30,		December 31,
(In thousands of U.S. dollars)		2012		2011
Deferred revenue, current	$	464	$	433
Deferred revenue, non-current		5,274		5,063
	$	5,738	$	5,496

Notes Payable (Tables)

9 Months Ended

Sep. 30, 2012

Notes Payable [Abstract]

Components Of Notes Payable


		September 30,		December 31,
(In thousands of U.S. dollars)		2012		2011
Loan agreement, The Bank of Tokyo-Mitsubishi UFJ, Ltd	$	12,800	$	12,900
Promissory notes, Sellers of SAG		48,383		46,727
	$	61,183	$	59,627

Notes payable, current	$	20,300	$	20,400
Notes payable, non-current		40,883		39,227
	$	61,183	$	59,627

Aggregated Scheduled Maturities Of Notes Payable


		September 30,
		2012
(In thousands)
Due in one year	$	20,300
Due in two years		8,837
Due in three years		8,938
Due in four years		9,045
Due in five years		9,156
Thereafter		4,907
	$	61,183

Collaboration And License Agreements (Tables)

9 Months Ended

Sep. 30, 2012

Abbott [Member]

Cash Streams And Related Revenue Recognized Or Deferred Under Agreement


		Amount Deferred at December 31,		Cash Received for the Nine Months Ended September 30,		Revenue Recognized for the Nine Months Ended September 30,		Foreign Currency Effects for the Nine Months Ended September 30,		Amount Deferred at September 30,
(In thousands of U.S. dollars)		2011		2012		2012		2012		2012
Collaboration revenue:
Up-front payment associated with the Company's
obligation to participate in joint committees	$	860	$	-	$	39	$	(7)	$	814

Research and development revenue:
Up-front payment	$	203	$	-	$	199	$	(4)	$	-
Development milestone payment		273		-		267		(6)	$	-
Total	$	476	$	-	$	466	$	(10)	$	-

Takeda [Member]

Cash Streams And Related Revenue Recognized Or Deferred Under Agreement


		Amount Deferred at December 31,		Cash Received for the Nine Months Ended September 30,		Revenue Recognized for the Nine Months Ended September 30,		Change in Accounts Receivable for the Nine Months Ended September 30,		Amount Deferred at September 30,
(In thousands of U.S. dollars)		2011		2012		2012		2012*		2012
Collaboration revenue:
Up-front payment associated with the Company's
obligation to participate in joint committees	$	1,323	$	-	$	110	$	-	$	1,213

Research and development revenue:
Reimbursement of research and development expenses	$	2,778	$	10,884	$	5,952	$	(4,533)	$	3,177

Product royalty revenue	$	-	$	35,614	$	36,521	$	907	$	-

Co-promotion revenue	$	-	$	3,407	$	3,253	$	(154)	$	-

* Includes billed and unbilled accounts receivable.

Stock Option Plans (Tables)

9 Months Ended

Sep. 30, 2012

Stock Plan 2001 [Member]

Employee Stock Option Activity


	Shares		Weighted Average Exercise Price Per Share	Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Options outstanding, December 31, 2011	190,400	$	10.00
Options expired	(34,000)		10.00
Options outstanding, September 30, 2012	156,400		10.00	3.59	$	-
Options exercisable, September 30, 2012	156,400		10.00	3.59	$	-

Stock Incentive Plan 2006 [Member]

Employee Stock Option Activity


	Shares		Weighted Average Exercise Price Per Share	Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Options outstanding, December 31, 2011	3,402,380	$	4.75
Options granted	428,850		6.53
Options exercised	(17,484)		3.86
Options forfeited	(380,870)		4.53
Options expired	(11,164)		11.21
Options outstanding, September 30, 2012	3,421,712		4.98	8.12	$	2,301,889
Options exercisable, September 30, 2012	881,407		6.01	6.25	$	616,952

Segment Reporting (Tables)

9 Months Ended

Sep. 30, 2012

Segment Reporting [Abstract]

Financial Information By Reportable Geographic Segment


(In thousands of U.S. dollars)		Americas		Europe		Asia		Consolidated
Three Months Ended September 30, 2012
Research and development revenue	$	665	$	72	$	-	$	737
Product royalty revenue		13,890		-		-		13,890
Co-promotion revenue		730		-		-		730
Contract and collaboration revenue		141		(15)		13		139
Total revenues		15,426		57		13		15,496
Research and development expenses		2,239		2,543		833		5,615
Depreciation and amortization		122		242		10		374
Other operating expenses		9,677		1,161		322		11,160
Income (loss) from operations		3,388		(3,889)		(1,152)		(1,653)
Interest income		65		3		-		68
Interest expense		-		(556)		(40)		(596)
Other non-operating expense		34		165		(191)		8
Loss before income taxes	$	3,487	$	(4,277)	$	(1,383)	$	(2,173)
Capital expenditures	$	41	$	-	$	-	$	41

Three Months Ended September 30, 2011
Research and development revenue	$	2,658	$	-	$	227	$	2,885
Product royalty revenue		10,563		-		-		10,563
Co-promotion revenue		769		-		-		769
Contract and collaboration revenue		141		-		14		155
Total revenues		14,131		-		241		14,372
Research and development expenses		6,552		965		1,208		8,725
Depreciation and amortization		215		167		(6)		376
Other operating expenses		9,014		403		376		9,793
Loss from operations		(1,650)		(1,535)		(1,337)		(4,522)
Interest income		32		2		1		35
Interest expense		-		(576)		(43)		(619)
Other non-operating income (expense), net		(10)		1,463		(229)		1,224
Loss before income taxes	$	(1,628)	$	(646)	$	(1,608)	$	(3,882)
Capital expenditures	$	15	$	3	$	86	$	104


(In thousands)		Americas		Europe		Asia		Consolidated
Nine Months Ended September 30, 2012
Research and development revenue	$	5,878	$	74	$	466	$	6,418
Product royalty revenue		36,521		-		-		36,521
Co-promotion revenue		3,253		-		-		3,253
Contract and collaboration revenue		424		(30)		39		433
Total revenues		46,076		44		505		46,625
Research and development expenses		6,250		5,405		2,547		14,202
Depreciation and amortization		366		709		30		1,105
Other operating expenses		32,475		2,576		916		35,967
Income (loss) from operations		6,985		(8,646)		(2,988)		(4,649)
Interest income		105		12		1		118
Interest expense		-		(1,656)		(124)		(1,780)
Other non-operating expense		67		82		578		727
Loss before income taxes	$	7,157	$	(10,208)	$	(2,533)	$	(5,584)
Capital expenditures	$	293	$	3,445	$	-	$	3,738

Nine Months Ended September 30, 2011
Research and development revenue	$	5,555	$	-	$	1,036	$	6,591
Product royalty revenue		30,724		-		-		30,724
Co-promotion revenue		2,768		-		-		2,768
Contract and collaboration revenue		424		-		39		463
Total revenues		39,471		-		1,075		40,546
Research and development expenses		19,465		2,352		4,021		25,838
Depreciation and amortization		668		325		33		1,026
Other operating expenses		33,232		807		941		34,980
Loss from operations		(13,894)		(3,484)		(3,920)		(21,298)
Interest income		155		3		2		160
Interest expense		-		(1,719)		(125)		(1,844)
Other non-operating income (expense), net		(21)		(1,779)		(233)		(2,033)
Loss before income taxes	$	(13,760)	$	(6,979)	$	(4,276)	$	(25,015)
Capital expenditures	$	93	$	6,003	$	188	$	6,284


As of September 30, 2012
Property and equipment, net	$	1,287	$	15	$	261	$	1,563
Identifiable assets, net of intercompany loans
and investments	$	95,849	$	14,507	$	10,775	$	121,131

As of December 31, 2011
Property and equipment, net	$	1,359	$	16	$	294	$	1,669
Identifiable assets, net of intercompany loans
and investments	$	96,490	$	47,925	$	13,154	$	157,569

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References + Details

Business Organization And Basis Of Presentation (Narrative) (Details)	9 Months Ended
	Sep. 30, 2012 item
Business Organization And Basis Of Presentation [Abstract]
Number of prostone products that received marketing approval	2
Number of additional prostones that have been developed	2
Number of gastrointestinal indications AMITIZA is being marketed for in U.S.	2
Period to meet terms and conditions of third party offer	45 days

Summary Of Significant Accounting Policies (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011
Significant Accounting Policies [Line Items]
Maturity of cash equivalents include all highly liquid investments maturity, days			90 days
Restricted cash	$ 18,700,000		$ 18,700,000		$ 17,200,000
Allowance for doubtful accounts	192,000		192,000
Cash insured by federal government	$ 4,600,000		$ 4,600,000		$ 15,600,000
Percentage of cash insured	5.60%		5.60%		16.70%
Percentage of Company's total accounts receivable	96.00%		96.00%		100.00%
Takeda [Member]
Significant Accounting Policies [Line Items]
Percentage of Company's revenues	98.70%	97.60%	98.00%	96.60%
Abbott [Member]
Significant Accounting Policies [Line Items]
Percentage of Company's revenues	0.10%	1.70%	1.10%	2.70%

Earnings Per Share (Computation Of Net Income (Loss) Per Share) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Basic net loss per share:
Net loss	$ (5,949)	$ (4,078)	$ (8,696)	$ (20,006)
Weighted average common shares outstanding	41,678	41,877	41,697	41,864
Basic net loss per share	$ (0.14)	$ (0.10)	$ (0.21)	$ (0.48)
Diluted net loss per share:
Net loss	$ (5,949)	$ (4,078)	$ (8,696)	$ (20,006)
Weighted average common shares outstanding for diluted net income per share	41,678	41,877	41,697	41,864
Diluted net loss per share	$ (0.14)	$ (0.10)	$ (0.21)	$ (0.48)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.21)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=16381557&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.23)
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 18
-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 36, 37, 38
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 20
-Article 5

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 21
-Article 9

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 10, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A7
-Appendix A

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 87-21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28, 29, 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References + Details

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Weighted-Average Number of Common Shares Outstanding
-URI http://asc.fasb.org/extlink&oid=6528421

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 171
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 40
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Earnings Per Share (Securities Excluded From Computation Of Diluted Net Loss Per Share) (Detail) - shares shares in Thousands	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Employee stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from computation of diluted net loss per share as their effect would be anti-dilutive	3,578	3,427
Non-employee stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from computation of diluted net loss per share as their effect would be anti-dilutive	450	450

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Antidilution
-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Diluted Earnings Per Share
-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Contingent Stock Agreement
-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 40
-Subparagraph c
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 13, 14
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 171
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Current And Non-Current Investments (Available-For-Sale Investments) (Details) - USD ($) $ in Thousands	Sep. 30, 2012	Dec. 31, 2011
Current [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	$ 6,229	$ 24,444
Unrealized Gains		11
Unrealized Losses		(3)
Fair Value	6,229	24,452
Current [Member] \| U.S. commercial paper [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	1,999	1,997
Unrealized Gains		3
Fair Value	1,999	2,000
Current [Member] \| Municipal securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	4,230
Fair Value	$ 4,230
Current [Member] \| U.S. government securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost		3,250
Fair Value		3,250
Current [Member] \| Corporate bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost		7,002
Unrealized Gains		8
Unrealized Losses		(3)
Fair Value		7,007
Current [Member] \| Variable rate demand notes [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost		12,195
Fair Value		12,195
Non-current [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost		1,000
Unrealized Losses		(2)
Fair Value		998
Non-current [Member] \| U.S. government securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost		1,000
Unrealized Losses		(2)
Fair Value		$ 998

Current And Non-Current Investments (Assets Measured At Fair Value On Recurring Basis) (Details) - USD ($) $ in Thousands	Sep. 30, 2012	Dec. 31, 2011
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	$ 31,372	$ 38,335
U.S. government securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value		4,248
U.S. commercial paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	3,499	2,000
Corporate bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	1,203	7,007
Money market funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	22,440	12,885
Variable rate demand notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	4,230	12,195
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	22,440	12,885
Fair Value, Inputs, Level 1 [Member] \| Money market funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	22,440	12,885
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	8,932	25,450
Fair Value, Inputs, Level 2 [Member] \| U.S. government securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value		4,248
Fair Value, Inputs, Level 2 [Member] \| U.S. commercial paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	3,499	2,000
Fair Value, Inputs, Level 2 [Member] \| Corporate bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	1,203	7,007
Fair Value, Inputs, Level 2 [Member] \| Variable rate demand notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	$ 4,230	$ 12,195

Intangible Assets (Details) - USD ($)	3 Months Ended		9 Months Ended
Intangible Assets (Details) - USD ($)	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Indefinite-lived Intangible Assets [Line Items]
Upfront payment made			$ 3,000,000	$ 3,000,000
Milestone payment maximum amount	$ 5,500,000		5,500,000
First milestone payment			500,000
Intangible assets	3,400,000		3,400,000
Non-current prepaid inventory	85,000		$ 85,000
Useful life of the underlying rights and data			10 years
Amortization Expense	85,000	$ 85,000	$ 256,000	256,000
Annual amortization expense			341,000
SAG [Member]
Indefinite-lived Intangible Assets [Line Items]
Upfront payment made			6,000,000
Milestone payment maximum amount	100,000,000		100,000,000
Intangible assets	6,000,000		$ 6,000,000
Useful life of the underlying rights and data			10 years
Amortization Expense	$ 153,000		$ 460,000	$ 300,000
Annual amortization expense			$ 613,000

Accrued Expenses (Schedule Of Accrued Expenses) (Details) - USD ($) $ in Thousands	Sep. 30, 2012	Dec. 31, 2011
Accrued Expenses [Abstract]
Research and development costs	$ 3,446	$ 5,622
Employee compensation	2,536	1,607
Selling and marketing costs	340	76
Legal service fees	732	1,955
RESCULA milestone	500	3,500
Other accrued expenses	1,246	888
Total	$ 8,800	$ 13,648

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

Commitments (Narrative) (Details) - USD ($)	3 Months Ended		9 Months Ended
Commitments (Narrative) (Details) - USD ($)	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Commitments [Abstract]
Rent expense for all operating leases	$ 426,000	$ 376,000	$ 1,200,000	$ 1,100,000
Research and development future estimated costs			$ 5,000,000

Commitments (Future Minimum, Non-Cancelable Lease Payments Under Operating Leases) (Details) $ in Thousands	Sep. 30, 2012 USD ($)
Commitments [Abstract]
2012 (October - December)	$ 412
2013	1,103
2014	1,024
2015	1,052
2016	1,084
2017 and thereafter	139
Total minimum lease payments	$ 4,814

Related Party Transactions (Narrative) (Details)	3 Months Ended		9 Months Ended
Related Party Transactions (Narrative) (Details)	Sep. 30, 2012 USD ($)	Sep. 30, 2011 USD ($)	Sep. 30, 2012 CHF (SFr)	Sep. 30, 2012 USD ($)	Sep. 30, 2011 USD ($)	Sep. 30, 2012 USD ($)	Sep. 30, 2011 CHF (SFr)	Sep. 30, 2011 USD ($)
Related Party Transaction [Line Items]
Increase in deferred revenue				$ (45,000)	$ (2,994,000)
R-Tech [Member]
Related Party Transaction [Line Items]
Contract and collaboration revenue	$ 112,000	$ 105,000		321,000	$ 314,000
Increase in deferred revenue				500,000
Numab [Member]
Related Party Transaction [Line Items]
Collateral deposited						$ 3,300,000
Loan utilized \| SFr			SFr 3,000,000
Collateral callable						$ 1,200,000
Equipment purchased on lease by Numab			544,000	$ 570,000
Remaining collateral balance \| SFr			SFr 4,500,000
Numab [Member] \| Maximum [Member]
Related Party Transaction [Line Items]
Collateral security for loan to Numab from third party							SFr 5,000,000	$ 5,200,000

Related Party Transactions (Expenses Under Agreements With R-Tech) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Related Party Transaction [Line Items]
Expenses related to R-Tech	$ 776	$ 114	$ 2,512	$ 244
Clinical supplies [Member]
Related Party Transaction [Line Items]
Expenses related to R-Tech	331		1,618
Other research and development services [Member]
Related Party Transaction [Line Items]
Expenses related to R-Tech	147	93	451	100
Commercial supplies [Member]
Related Party Transaction [Line Items]
Expenses related to R-Tech	$ 298	$ 21	$ 443	$ 144

Related Party Transactions (Deferred Revenue Resulting From Deferral Of Upfront Payments Relating To Exclusive Supply Agreements With R-Tech) (Details) - USD ($) $ in Thousands	Sep. 30, 2012	Dec. 31, 2011
Deferred Revenue Arrangement [Line Items]
Deferred revenue, current	$ 3,841	$ 3,888
Deferred revenue, non-current	7,101	7,045
R-Tech [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue, current	464	433
Deferred revenue, non-current	5,274	5,063
Deferred Revenue, Total	$ 5,738	$ 5,496

- Definition

The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References + Details

Notes Payable (Narrative) (Details)	9 Months Ended
Notes Payable (Narrative) (Details)	Sep. 30, 2012 USD ($)	Sep. 30, 2011 USD ($)	Sep. 30, 2012 JOD (JD)	Sep. 30, 2012 USD ($)	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)
Debt Instrument [Line Items]
Effective date of interest rate			Jun. 01, 2012	Jun. 01, 2012
Interest expense added to principal balance of notes	$ 1,656,000	$ 1,719,000
Kuno Trust [Member]
Debt Instrument [Line Items]
Debt Face amount						$ 25,900,000
Secured Debt [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity \| JD			JD 1,000,000,000
Loan Agreement Extension of Credit Period	1 year
Interest description	The loan bears annual interest based on the three-month Tokyo Interbank Offer Rate, plus 1% and is reset quarterly.
Loan Agreement, interest rate	1.24%
Loan agreement outstanding balance				$ 12,800,000	$ 12,900,000
Deposits in bank				$ 14,900,000
Percentage of annual interest deposits with banks bear			0.40%	0.40%
Interest rate above variable rate			1.00%	1.00%
Secured Debt [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Minimum percentage of collateral to loan			90.00%	90.00%
Subordinated Unsecured Promissory Notes [Member]
Debt Instrument [Line Items]
Interest description	The interest rate for the notes is equal to the per annum rate of interest determined on the basis of the sum of London Interbank Offered Rate, plus 4.0%, and is reset every six months on December 1st and June 1st of each year.
Debt Face amount						51,900,000
Interest rate			4.70%	4.70%
Notes Repayment Schedule	The notes provide for annual payments of the first two payments on December 31, 2011 and 2012, respectively, and then for a semi-annual payment schedule of interest and principal over a seven-year period on each June 1st and December 1st, provided that, until December 1, 2012 all accrued and unpaid interest will not be paid in cash but instead added to the principal balance of the notes. Ambrent made one principal payment on December 1, 2011 and is scheduled to make the next principal payment on December 1, 2012.
Subordinated Unsecured Promissory Notes [Member] \| LIBOR [Member]
Debt Instrument [Line Items]
Interest rate above variable rate			4.00%	4.00%
Subordinated Unsecured Promissory Notes [Member] \| Ueno Trust [Member]
Debt Instrument [Line Items]
Debt Face amount						$ 25,900,000

Notes Payable (Schedule Of Notes Payable) (Details) - USD ($) $ in Thousands	Sep. 30, 2012	Dec. 31, 2011
Notes Payable [Abstract]
Loan agreement, The Bank of Tokyo-Mitsubishi UFJ, Ltd	$ 12,800	$ 12,900
Promissory notes, Sellers of SAG	48,383	46,727
Notes payable, total	61,183	59,627
Notes payable, current	20,300	20,400
Notes payable, non-current	$ 40,883	$ 39,227

Notes Payable (Aggregated Scheduled Maturities Of Notes Payable) (Details) - USD ($) $ in Thousands	Sep. 30, 2012	Dec. 31, 2011
Notes Payable [Abstract]
Due in one year	$ 20,300
Due in two years	8,837
Due in three years	8,938
Due in four years	9,045
Due in five years	9,156
Thereafter	4,907
Notes payable, total	$ 61,183	$ 59,627

Collaboration And License Agreements - (Narrative) (Details) - USD ($) $ in Millions	1 Months Ended	9 Months Ended	12 Months Ended
	Oct. 31, 2011	Sep. 30, 2012	Dec. 31, 2009
Takeda [Member] \| Up Front Fee And Milestone Payment Arrangement [Member]
Segment Reporting Information [Line Items]
Upfront & Development Milestone payment Received		$ 150.0
Abbott [Member]
Segment Reporting Information [Line Items]
Upfront & Development expected Milestone receivables		15.0
Abbott [Member] \| Up Front Fee And Milestone Payment Arrangement [Member]
Segment Reporting Information [Line Items]
Upfront & Development Milestone payment Received		$ 22.5
Abbott [Member] \| Up-front Payment Arrangement [Member]
Segment Reporting Information [Line Items]
Upfront & Development Milestone payment Received			$ 10.0
Abbott [Member] \| Milestone Payment Arrangement [Member]
Segment Reporting Information [Line Items]
Upfront & Development Milestone payment Received	$ 5.0		$ 7.5

Collaboration And License Agreements (Cash Streams And Related Revenue Recognized Or Deferred Under Abbott Agreement) (Details) - Abbott [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2012 USD ($)
Collaborative Arrangement [Member] \| Up-front Payment Arrangement [Member]
Deferred Revenue Arrangement [Line Items]
Beginning Balance	$ 860
Revenue Recognized	39
Ending Balance	814
Research and Development Arrangement [Member]
Deferred Revenue Arrangement [Line Items]
Beginning Balance	476
Revenue Recognized	466
Research and Development Arrangement [Member] \| Up-front Payment Arrangement [Member]
Deferred Revenue Arrangement [Line Items]
Beginning Balance	203
Revenue Recognized	199
Research and Development Arrangement [Member] \| Milestone Payment Arrangement [Member]
Deferred Revenue Arrangement [Line Items]
Beginning Balance	273
Revenue Recognized	267
Foreign Currency Translation Adjustment Gain (Loss) [Member] \| Collaborative Arrangement [Member] \| Up-front Payment Arrangement [Member]
Deferred Revenue Arrangement [Line Items]
Deferred Revenue Additions	(7)
Foreign Currency Translation Adjustment Gain (Loss) [Member] \| Research and Development Arrangement [Member]
Deferred Revenue Arrangement [Line Items]
Deferred Revenue Additions	(10)
Foreign Currency Translation Adjustment Gain (Loss) [Member] \| Research and Development Arrangement [Member] \| Up-front Payment Arrangement [Member]
Deferred Revenue Arrangement [Line Items]
Deferred Revenue Additions	(4)
Foreign Currency Translation Adjustment Gain (Loss) [Member] \| Research and Development Arrangement [Member] \| Milestone Payment Arrangement [Member]
Deferred Revenue Arrangement [Line Items]
Deferred Revenue Additions	$ (6)

Collaboration And License Agreements (Cash Streams And Related Revenue Recognized Or Deferred Under Takeda Agreements) (Details) - Takeda [Member]
$ in Thousands

9 Months Ended

Sep. 30, 2012

USD ($)

Royalty Arrangement [Member]

Deferred Revenue Arrangement [Line Items]

Revenue Recognized

$ 36,521

Collaborative Arrangement, Co-promotion [Member]

Deferred Revenue Arrangement [Line Items]

Revenue Recognized

3,253

Collaborative Arrangement [Member] | Up-front Payment Arrangement [Member]

Deferred Revenue Arrangement [Line Items]

Beginning Balance

1,323

Revenue Recognized

110

Ending Balance

1,213

Research and Development Arrangement [Member]

Deferred Revenue Arrangement [Line Items]

Beginning Balance

2,778

Revenue Recognized

5,952

Ending Balance

3,177

Cash [Member] | Royalty Arrangement [Member]

Deferred Revenue Arrangement [Line Items]

Deferred Revenue Additions

35,614

Cash [Member] | Collaborative Arrangement, Co-promotion [Member]

Deferred Revenue Arrangement [Line Items]

Deferred Revenue Additions

3,407

Cash [Member] | Research and Development Arrangement [Member]

Deferred Revenue Arrangement [Line Items]

Deferred Revenue Additions

10,884

Accounts Receivable [Member] | Royalty Arrangement [Member]

Deferred Revenue Arrangement [Line Items]

Deferred Revenue Additions

907

^[1]

Accounts Receivable [Member] | Collaborative Arrangement, Co-promotion [Member]

Deferred Revenue Arrangement [Line Items]

Deferred Revenue Additions

(154)

^[1]

Accounts Receivable [Member] | Research and Development Arrangement [Member]

Deferred Revenue Arrangement [Line Items]

Deferred Revenue Additions

$ (4,533)

^[1]

[1]	Includes billed and unbilled accounts receivable.

Stock Option Plans (Narrative) (Details) - USD ($)	1 Months Ended	9 Months Ended		12 Months Ended
Stock Option Plans (Narrative) (Details) - USD ($)	Aug. 31, 2005	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011
Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]
Options granted to employees and directors, weighted average grant date fair value		$ 6.53		$ 1.81
Options granted to employees and directors, unrecognized compensation cost		$ 2,600,000
Options granted to employees and directors related to non-vested awards, weighted average period of recognition		2 years 5 months 16 days
Class A common stock purchased		$ 16,000
Stock Plan 2001 [Member]
Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]
Options granted to non-employees, shares outstanding and exercisable		156,400
Options granted to non-employees, shares exercisable, remaining contractual life		3 years 7 months 2 days
Stock Plan 2001 [Member] \| Non-employee stock options [Member]
Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]
Options granted	510,000
Options granted, exercise price	$ 5.85
Options granted to non-employees, shares outstanding and exercisable		450,000		450,000
Options granted to non-employees, shares vested, exercise price		$ 5.85		$ 5.85
Options granted to non-employees, shares exercisable, remaining contractual life		2 years 7 months 2 days		3 years 3 months 29 days
Stock Incentive Plan 2006 [Member]
Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]
Options granted		428,850
Options granted, exercise price		$ 6.53
Options granted to non-employees, shares outstanding and exercisable		881,407
Options granted to non-employees, shares exercisable, remaining contractual life		6 years 3 months
Options granted to non-employees, shares outstanding intrinsic value		$ 2,301,889
Options granted to non-employees, shares exercisable intrinsic value		$ 616,952
Stock Incentive Plan 2006 [Member] \| Employee Stock Purchase Plan [Member]
Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]
Class A common stock purchased, shares		2,471	2,136
Class A common stock purchased		$ 15,266	$ 8,133

Stock Option Plans (Employee Stock Option Activity Under Company's 2001 Incentive Plan) (Details) - Stock Plan 2001 [Member]	9 Months Ended
	Sep. 30, 2012 $ / shares shares
Shares
Options outstanding, beginning balance \| shares	190,400
Options expired \| shares	(34,000)
Options outstanding, ending balance \| shares	156,400
Options exercisable, ending balance \| shares	156,400
Weighted Average Exercise Price Per Share
Options outstanding, beginning balance \| $ / shares	$ 10.00
Options expired \| $ / shares	10.00
Options outstanding, ending balance \| $ / shares	10.00
Options exercisable, ending balance \| $ / shares	$ 10.00
Weighted Average Remaining Contractual Term (Years)
Options outstanding, ending balance	3 years 7 months 2 days
Options exercisable, ending balance	3 years 7 months 2 days

Stock Option Plans (Employee Stock Option Activity Under Company's Amended And Restated 2006 Stock Incentive Plan) (Details) - Stock Incentive Plan 2006 [Member]	9 Months Ended
	Sep. 30, 2012 USD ($) $ / shares shares
Shares
Options outstanding, beginning balance \| shares	3,402,380
Options granted \| shares	428,850
Options exercised \| shares	(17,484)
Options forfeited \| shares	(380,870)
Options expired \| shares	(11,164)
Options outstanding, ending balance \| shares	3,421,712
Options exercisable, ending balance \| shares	881,407
Weighted Average Exercise Price Per Share
Options outstanding, beginning balance \| $ / shares	$ 4.75
Options granted \| $ / shares	6.53
Options exercised \| $ / shares	3.86
Options forfeited \| $ / shares	4.53
Options expired \| $ / shares	11.21
Options outstanding, ending balance \| $ / shares	4.98
Options exercisable, ending balance \| $ / shares	$ 6.01
Weighted Average Remaining Contractual Term (Years)
Options outstanding, ending balance	8 years 1 month 13 days
Options exercisable, ending balance	6 years 3 months
Aggregate Intrinsic Value
Options outstanding, ending balance \| $	$ 2,301,889
Options exercisable, ending balance \| $	$ 616,952

Income Taxes (Details) - USD ($)	3 Months Ended			9 Months Ended
Income Taxes (Details) - USD ($)	Sep. 30, 2012	Jun. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Income Taxes [Abstract]
Income tax provision (benefit)	$ 3,776,000		$ 196,000	$ 3,112,000	$ (5,009,000)
Net discrete benefit	557,000			1,300,000
Benefit related to return to provision adjustments	812,000
Amortization of deferred charge	185,000			372,000
Benefit related to intellectual property transfer adjustment				778,000
Tax benefit on settlement of a tax audit with Japanese tax authorities				351,000
Tax expense related to stock option forfeitures				158,000
Discrete tax benefit (provision)	(84,000)	$ 778,000		268,000
Decrease in deferred charges	23,800,000			23,800,000
Decrease in deferred tax liability	24,100,000			24,100,000
Outstanding non-current income tax liability for uncertain tax positions	$ 1,200,000			1,200,000
Decrease in income tax liability				$ 283,000

Segment Reporting (Financial Information By Reportable Geographic Segment) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011
Segment Reporting Information [Line Items]
Research and development revenue	$ 737	$ 2,885	$ 6,418	$ 6,591
Product royalty revenue	13,890	10,563	36,521	30,724
Co-promotion revenue	730	769	3,253	2,768
Contract and collaboration revenue	139	155	433	463
Total revenues	15,496	14,372	46,625	40,546
Research and development expenses	5,615	8,725	14,202	25,838
Depreciation and amortization	374	376	1,105	1,026
Other operating expenses	11,160	9,793	35,967	34,980
Income (loss) from operations	(1,653)	(4,522)	(4,649)	(21,298)
Interest income	68	35	118	160
Interest expense	(596)	(619)	(1,780)	(1,844)
Other non-operating income (expense), net	8	1,224	727	(2,033)
Loss before income taxes	(2,173)	(3,882)	(5,584)	(25,015)
Capital expenditures	41	104	3,738	6,284
Property and equipment, net	1,563		1,563		$ 1,669
Identifiable assets, net of intercompany loans and investments	121,131		121,131		157,569
Americas [Member]
Segment Reporting Information [Line Items]
Research and development revenue	665	2,658	5,878	5,555
Product royalty revenue	13,890	10,563	36,521	30,724
Co-promotion revenue	730	769	3,253	2,768
Contract and collaboration revenue	141	141	424	424
Total revenues	15,426	14,131	46,076	39,471
Research and development expenses	2,239	6,552	6,250	19,465
Depreciation and amortization	122	215	366	668
Other operating expenses	9,677	9,014	32,475	33,232
Income (loss) from operations	3,388	(1,650)	6,985	(13,894)
Interest income	65	32	105	155
Other non-operating income (expense), net	34	(10)	67	(21)
Loss before income taxes	3,487	(1,628)	7,157	(13,760)
Capital expenditures	41	15	293	93
Property and equipment, net	1,287		1,287		1,359
Identifiable assets, net of intercompany loans and investments	95,849		95,849		96,490
Europe [Member]
Segment Reporting Information [Line Items]
Research and development revenue	72		74
Contract and collaboration revenue	(15)		(30)
Total revenues	57		44
Research and development expenses	2,543	965	5,405	2,352
Depreciation and amortization	242	167	709	325
Other operating expenses	1,161	403	2,576	807
Income (loss) from operations	(3,889)	(1,535)	(8,646)	(3,484)
Interest income	3	2	12	3
Interest expense	(556)	(576)	(1,656)	(1,719)
Other non-operating income (expense), net	165	1,463	82	(1,779)
Loss before income taxes	(4,277)	(646)	(10,208)	(6,979)
Capital expenditures		3	3,445	6,003
Property and equipment, net	15		15		16
Identifiable assets, net of intercompany loans and investments	14,507		14,507		47,925
Asia [Member]
Segment Reporting Information [Line Items]
Research and development revenue		227	466	1,036
Contract and collaboration revenue	13	14	39	39
Total revenues	13	241	505	1,075
Research and development expenses	833	1,208	2,547	4,021
Depreciation and amortization	10	(6)	30	33
Other operating expenses	322	376	916	941
Income (loss) from operations	(1,152)	(1,337)	(2,988)	(3,920)
Interest income		1	1	2
Interest expense	(40)	(43)	(124)	(125)
Other non-operating income (expense), net	(191)	(229)	578	(233)
Loss before income taxes	(1,383)	(1,608)	(2,533)	(4,276)
Capital expenditures		$ 86		$ 188
Property and equipment, net	261		261		294
Identifiable assets, net of intercompany loans and investments	$ 10,775		$ 10,775		$ 13,154